ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-c-Kit/MMAE Antibody-Drug Conjugate NN3201

Its studies are mostly in Gastrointestinal Stromal Tumors, led by Novelty Nobility.

Furthest: phase 1, since Jan 8, 20251 company-led study, 1 open or runningNext primary completion: Aug 30, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novelty Nobility11 open or runningphase 1since Jan 8, 2025Jan 8, 2025Aug 30, 2027phase 1 · NCT06805825

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 8, 2025First study: phase 1 study in Gastrointestinal Stromal TumorsFirst studyNCT06805825 · 67 planned · United States

Ahead

  1. Aug 30, 2027Primary completion: phase 1 study in Gastrointestinal Stromal TumorsNCT06805825

TargetBeta

KIT →read by rule
“An antibody-drug conjugate (ADC) composed of 2G4, a human monoclonal antibody directed against the stem cell factor receptor c-Kit (SCFR; KIT; CD117), ”NCIt, by rule

Other programs on KIT

ProgramCompanyFurthest phaseStudies
imatinibruleNovartisphase 470
regorafenibruleBayerphase 440
AvapritinibruleSanofiphase 410
anlotinibruleSino Biopharmaceuticalphase 340
masitinibruleAB Sciencephase 338
quizartinibruleDaiichi Sankyophase 322
ripretinibruleOno Pharmaceuticalphase 39
velzatinibGlaxoSmithKlinephase 38
seralutinibrulegb002-inc-a-wholly-owned-subsidiary-of-gossamer-bio-incphase 38
elenestinibSanofiphase 33
NB-003ruleningbo-newbay-technology-development-co-ltdphase 32
briquilimabrulejasper-therapeutics-incphase 27

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06805825Gastrointestinal Stromal Tumors · United States1RecruitingAug 30, 202767

How it is read

Names in the registry

  • “NN3201”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.